<DOC>
	<DOC>NCT01146171</DOC>
	<brief_summary>The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies</brief_summary>
	<brief_title>Japanese Phase 1 Study of BMS-844203 (CT322)</brief_title>
	<detailed_description />
	<criteria>Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate Life expectancy of at least 3 months Eastern Cooperative Oncology Group performance 01 Subject has uncontrolled diabetes or hypertension Clinical significant bleeding diathesis or coagulopathy Thrombotic or embolic cerebrovascular accident</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>